News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

13,751 Results

Type

Article (612)
Company Profile (2)
Press Release (13137)

Section

Business (3740)
Career Advice (1)
Deals (876)
Drug Development (1338)
Employer Resources (2)
FDA (273)
Job Trends (150)
News (6330)
Policy (538)

Tag

Date

Today (1)
Last 7 days (8)
Last 30 days (37)
Last 365 days (489)
2025 (87)
2024 (511)
2023 (610)
2022 (1919)
2021 (1699)
2020 (1173)
2019 (810)
2018 (515)
2017 (703)
2016 (572)
2015 (801)
2014 (626)
2013 (520)
2012 (595)
2011 (521)
2010 (460)

Location

Africa (5)
Arizona (1)
Asia (664)
Australia (185)
California (25)
Canada (20)
China (2)
Europe (5469)
Florida (6)
Idaho (1)
Illinois (8)
Indiana (1)
Japan (4)
Maryland (5)
Massachusetts (47)
Michigan (5)
New Jersey (13)
New York (8)
North Carolina (6)
Northern California (14)
Pennsylvania (44)
South America (20)
Southern California (7)
Texas (2)
Utah (5)
Wisconsin (1)

Filters

Type

Article (612)
Company Profile (2)
Press Release (13137)

Section

Business (3740)
Career Advice (1)
Deals (876)
Drug Development (1338)
Employer Resources (2)
FDA (273)
Job Trends (150)
News (6330)
Policy (538)

Tag

Date

Today (1)
Last 7 days (8)
Last 30 days (37)
Last 365 days (489)
2025 (87)
2024 (511)
2023 (610)
2022 (1919)
2021 (1699)
2020 (1173)
2019 (810)
2018 (515)
2017 (703)
2016 (572)
2015 (801)
2014 (626)
2013 (520)
2012 (595)
2011 (521)
2010 (460)

Location

Africa (5)
Arizona (1)
Asia (664)
Australia (185)
California (25)
Canada (20)
China (2)
Europe (5469)
Florida (6)
Idaho (1)
Illinois (8)
Indiana (1)
Japan (4)
Maryland (5)
Massachusetts (47)
Michigan (5)
New Jersey (13)
New York (8)
North Carolina (6)
Northern California (14)
Pennsylvania (44)
South America (20)
Southern California (7)
Texas (2)
Utah (5)
Wisconsin (1)

13,751 Results for "mundipharma edo gmbh".

Sort By

Press Releases

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

March 5, 2025
·
7 min read
Press Releases

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

December 16, 2024
·
5 min read
Drug Development

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of DMD

PepGen Inc. announced that the UK Medicines & Healthcare products Regulatory Agency has authorized its Clinical Trial Application to initiate the CONNECT2-EDO51 Phase 2 clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy amenable to an exon 51-skipping approach.

March 4, 2024
·
7 min read
Press Releases

Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH

March 19, 2025
·
1 min read
Biotech Beach

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Cidara Therapeutics, Inc. announced that it has entered into an asset purchase agreement with its current partner, Mundipharma*, for the divestiture of rezafungin.

April 24, 2024
·
4 min read
Drug Development

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

PepGen Inc. announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose clinical trial evaluating PGN-EDO51 for the treatment of Duchenne muscular dystrophy patients amendable to an exon 51 skipping therapy.

January 8, 2024
·
7 min read
Press Releases

T-CURX GmbH Enters into Technology Access Agreement with Kytopen

February 14, 2025
·
5 min read
Policy

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. announced that the U.S. Food and Drug Administration granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy patients whose mutations are amenable to an exon 51 skipping approach.

March 13, 2024
·
7 min read
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. announced the execution of an Assignment Agreement with Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. for the commercialization of FOLOTYN® in the People’s Republic of China.

August 1, 2023
·
7 min read
Press Releases

Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers

February 25, 2025
·
3 min read

1 of 1,376

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin